Logo

Evogene Closes US IPO, Raising $84.8M

Nov 27, 2013 | staff reporter

NEW YORK (GenomeWeb News) – Evogene today announced the closing of its US initial public offering, raising $84.8 million in gross proceeds.

The Israel-based plant genomics firm went public in the US last week. It said today that underwriters on the offering exercised their option in full to purchase up to 750,000 additional shares at $14.75 per share, the same price as in its public offering. Credit Suisse Securities and Deutsche Bank Securities were joint book-running managers, while Oppenheimer and Piper Jaffray were co-managers on the offering.

The company, which also trades on the Tel Aviv Stock Exchange, filed to go public in the US in September, saying at the time that it intended to offer $60 million of its shares.

Filed under

IPO
plant genomics
Evogene
Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.